CABENUVA KIT

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jan 21, 2021

   5 yr 6 mo ago

2. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Jan 21, 2026

   5 mo ago

3. Patent 10927129 expires

   Listed drug substance patent expiration.

   Apr 28, 2026

   2 mo ago

4. Today

5. Patent 11389447 expires

   Listed method-of-use patent (U-3405) expiration.

   Jun 30, 2027

   in 1 yr 1 mo

6. Patent 8410103 expires

   Listed drug substance patent expiration.

   Feb 04, 2031

   in 4 yr 8 mo

7. Patent 11224597 expires

   Listed drug product patent expiration.

   Sep 15, 2031

   in 5 yr 4 mo

8. Patent 12138264 expires

   Listed drug product patent expiration.

   Sep 15, 2031

   in 5 yr 4 mo

9. Patent RE50189 expires

   Listed method-of-use patent (U-3348) expiration.

   Nov 27, 2031

   in 5 yr 6 mo

10. Patent 11389448 expires

    Listed drug product patent expiration.

    Apr 13, 2032

    in 5 yr 11 mo

11. Patent 12178815 expires

    Listed method-of-use patent (U-3348) expiration.

    Jul 18, 2038

    in 12 yr 3 mo

12. Patent 12636285 expires

    Listed method-of-use patent (U-3348) expiration.

    Oct 01, 2040

    in 14 yr 6 mo

13. Patent 12636286 expires

    Listed method-of-use patent (U-3348) expiration.

    Oct 01, 2040

    in 14 yr 6 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Jan 21, 2026

  5 mo ago

Listed patents (10)